Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13

被引:15
作者
Coon, Cheryl D. [1 ]
Schlichting, Michael [2 ]
Zhang, Xinke [3 ]
机构
[1] Outcometrix, Salida, CO 81201 USA
[2] Merck Healthcare KGaA, Darmstadt, Germany
[3] Merck KGaA, EMD Serono Res & Dev Inst Inc, Billerica, MA USA
关键词
QUALITY-OF-LIFE; MINIMAL IMPORTANT DIFFERENCES; CLINICAL-TRIALS; REPORTED OUTCOMES; SCORES;
D O I
10.1007/s40271-022-00584-w
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction When determining if changes on patient-reported outcome (PRO) scores in clinical trials convey a meaningful treatment benefit, statistical significance tests alone may not communicate the patient perspective. Appraising within-patient changes on PRO scores against established thresholds can determine if improvements or deteriorations experienced by individuals are meaningful. To evaluate the appropriateness of thresholds for interpreting meaningful improvements and deterioration within individuals on the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core instrument (QLQ-C30) and 13-item lung cancer module (QLQ-LC13), a series of psychometric methods were applied to data from a phase III randomized controlled clinical trial in non-small cell lung cancer. Methods Anchor-based methods of empirical cumulative distribution functions and classification statistics were employed using change scores from Baseline to Week 7 using changes on the QLQ-C30 Global Health Status item as an anchor. Distribution-based methods of one-half standard deviation and standard error of measurement identified the minimum amount of change each domain score can reliably measure. Results While the correlations between the domain scores and the anchor item were modest in size (i.e., r >= 0.30 for only 5 of 24 domains), consideration of multiple methods along with the magnitude of possible step changes on the score allowed for patterns to emerge. The triangulation process planned a priori resulted in different methods being the source for different domain scores. Absolute values of the proposed thresholds ranged from 11.11 to 33.33, and all resulted in the same classifications for all EORTC domains, except QLQ-C30 Fatigue, as would the 10-point threshold that is traditionally used. Conclusion This study confirms the appropriateness of the 10-point EORTC score threshold generally used by the field for interpreting within-patient changes, but the thresholds proposed from this study enhance interpretability by corresponding to only observable locations along the domain score scale.
引用
收藏
页码:691 / 702
页数:12
相关论文
共 25 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
[Anonymous], 2009, FED REGISTER, V74, P65132
[3]  
[Anonymous], 2021, XALKORI
[4]  
Barlesi F, 2016, ANN ONCOL, V27
[5]   Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J].
Barlesi, Fabrice ;
Vansteenkiste, Johan ;
Spigel, David ;
Ishii, Hidenobu ;
Garassino, Marina ;
de Marinis, Filippo ;
Ozguroglu, Mustafa ;
Szczesna, Aleksandra ;
Polychronis, Andreas ;
Uslu, Ruchan ;
Krzakowski, Maciej ;
Lee, Jong-Seok ;
Calabro, Luana ;
Frontera, Osvaldo Aren ;
Ellers-Lenz, Barbara ;
Bajars, Marcis ;
Ruisi, Mary ;
Park, Keunchil .
LANCET ONCOLOGY, 2018, 19 (11) :1468-1479
[6]  
Beaumont J, 2021, 28 ANN C INT SOC QUA
[7]   Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer [J].
Bedard, Gillian ;
Zeng, Liang ;
Zhang, Liying ;
Lauzon, Natalie ;
Holden, Lori ;
Tsao, May ;
Danjoux, Cyril ;
Barnes, Elizabeth ;
Sahgal, Arjun ;
Poon, Michael ;
Chow, Edward .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (02) :109-117
[8]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[9]   Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials [J].
Cocks, Kim ;
King, Madeleine T. ;
Velikova, Galina ;
Fayers, Peter M. ;
Brown, Julia M. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (13) :1793-1798
[10]   Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores [J].
Coon, Cheryl D. ;
Cook, Karon F. .
QUALITY OF LIFE RESEARCH, 2018, 27 (01) :33-40